From a Device to a Care Pathway

The evidence becomes useful only when we ask what hearing care actually involves. The practical question is not whether a device can be named as a dementia treatment, but how a person moves from possible hearing loss to suitable assessment, fitting, supported use and follow-up—and how cost, stigma and service capacity can interrupt that path. This chapter uses ACHIEVE and the WHO guidance to describe responsible hearing care in general terms, while keeping any cognitive protection as a possible secondary benefit rather than an individual promise.

The intervention begins before the device

A hearing aid is not the first step in hearing care. The first step is recognizing that hearing may be limiting communication and arranging an assessment that can characterize the problem and determine whether conventional amplification is suitable. WHO guidance calls for prevention, screening and management of hearing loss, and describes systematic screening of adults above 50 followed by prompt diagnosis and hearing-aid fitting through community-based services. The point of screening is not to label everyone for the same device. It is to make a hidden or normalized problem visible early enough for an appropriate response.

Assessment matters because “hearing loss” is not one uniform exposure. ACHIEVE selected adults with adult-onset bilateral hearing loss in a range expected to benefit from conventional hearing aids and related audiological services. It excluded people with permanent conductive hearing loss, recent hearing-aid use, substantial cognitive impairment and other conditions that would make the study intervention unsuitable or difficult to evaluate. WHO also says that the effectiveness of an intervention may vary with the type and severity of hearing loss and the extent to which a device is used.

That boundary has two practical consequences. First, a hearing aid should be treated as one possible response to an assessed hearing problem, not as a universal answer to every difficulty hearing. Second, the cognitive evidence from ACHIEVE is most directly relevant to people resembling its participants: community-dwelling adults aged 70–84 who were cognitively normal, had aidable adult-onset bilateral loss and had not recently used hearing aids. It does not directly establish what a person with established dementia, a different type or severity of hearing loss, a need for a cochlear implant or a different care setting will experience.

The WHO recommendation is broader in one respect. It allows hearing aids to be offered to adults with hearing loss who have normal cognition or mild cognitive impairment, but the guideline also says that evidence in adults with MCI is limited. The broader recommendation should not be mistaken for evidence that ACHIEVE studied MCI. Nor should ACHIEVE's selected population be treated as a reason to withhold hearing care from everyone outside it. The responsible conclusion is simply that the cognitive claim becomes less certain as the population and intervention move away from what was studied.

Once a suitable hearing intervention is identified, fitting is part of the treatment rather than a cosmetic final step.